Hester Biosciences Q2FY26 Profit Surges 71% on Consolidated Basis; Standalone Profit Declines 23%

Ahmedabad, November 12, 2025: Hester Biosciences Ltd. reported its financial results for the quarter ended September 30, 2025, posting a 71% year-on-year rise in consolidated profit after tax (PAT) to ₹143.31 million, while standalone PAT declined 23% to ₹72.09 million.

The strong consolidated growth was driven by robust performance from overseas subsidiaries, which helped offset the impact of delayed institutional orders on the domestic front. Following the announcement, Hester Biosciences’ shares closed 3% higher on Wednesday.

Key Financial Highlights (₹ in million)

During the quarter, the company’s standalone divisional sales declined 12% year-on-year (YoY) to ₹645.06 million from ₹734.82 million in Q2 FY25. The standalone profit after tax (PAT) also fell 23% YoY to ₹72.09 million from ₹93.36 million a year earlier. On a consolidated basis, the company reported sales revenue of ₹708.96 million, reflecting a 15% YoY drop from ₹836.72 million in the same quarter last year. Despite this, the consolidated PAT surged 71% to ₹143.31 million in Q2 FY26 compared to ₹83.91 million in Q2 FY25, driven by strong subsidiary performance abroad.

Profitability Snapshot

Hester’s standalone gross margin remained stable at 68%, underscoring efficient cost management. However, standalone EBITDA fell 17% YoY to ₹133.55 million due to lower institutional demand. On the other hand, the consolidated EBITDA rose 7% YoY to ₹235.97 million, while consolidated PAT jumped 71% to ₹143.31 million, reflecting the company’s solid international growth and operational efficiency across global markets.

Share Price Update

Hester Biosciences share price closed with a 3.06% gain. The stock opened at ₹1,639, hit a high of ₹1,780, and a low of ₹1,573. The share price of Hester Biosciences has dipped 34% in the last year, 3% in the last six months, and 4.37% in the previous month.

Hester Biosciences Ltd., established in 1997, is one of India’s leading animal health companies with operations spanning two major divisions — Poultry Healthcare and Animal Healthcare. The company is recognised as the world’s largest manufacturer of the PPR vaccine, holding nearly 75% of the global market share. In addition, Hester is a key player in Goat Pox and Poultry vaccines. Its manufacturing capabilities extend across multiple advanced vaccine platforms, including chick embryo origin and tissue culture technologies, reinforcing its strong position in the global animal healthcare industry.

REF: https://nsearchives.nseindia.com/corporate/HESTERBIO_12112025114035_20251112Q2_H1FY26PressRelease.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations